Article Text

Download PDFPDF
Medicines update

Statistics from

The points below highlight changes in marketing authorisations (MAs) that may have a significant impact on veterinary surgeons’ prescribing decisions.

New marketing authorisations

New marketing authorisations relevant to veterinary surgeons in the UK that were issued or published in September 2018 are listed in Table 1.

View this table:
Table 1: Marketing authorisations issued and/or published in September 2018

Of those products listed, the VMD draws attention to:

• Cortico Veyxin 10 mg/ml suspension for injection is the first injectable product containing prednisolone acetate authorised for use in cats, cattle, dogs and horses. The product is indicated in all target species for treatment of acute non-infectious arthritis, bursitis, tenosynovitis or allergic skin disease, and in cattle only for supportive treatment of primary ketosis (acetonaemia).

• Merlin 1.04 g medicated collar for large sized dogs is among the first of the deltamethrin products for dogs to be indicated for treatment of fleas (Ctenocephalides felis) with a persistent killing activity for 16 weeks. The product is also indicated for treatment of ticks (Ixodes ricinus) with persistent killing activity for 6 months, and treatment of sandflies (Phlebotomus perniciosus), with persistent anti-feeding and killing activity for 5.5 months.

Table 1 also indicates where a public assessment report should …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.